• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

What Approaches Can Companies Use to Create Drugs With Disease-Modifying Effects and to Treat Early-Stage Disease?

Posted on: Monday, 4 December 2006, 09:01 CST

Research and Markets (http://www.researchandmarkets.com/reports/c46402) has announced the addition of the Decision Resources report "Industry Analysis: Where Is the Innovation in Neurology Markets?" to their offering.

The four major neurological diseases currently have no cures. Many pharmaceuticals are available and are in development, but these drugs typically address just the symptoms. Vast unmet need exists for medicines that treat the early stages of neurological diseases. And, in turn, a huge opportunity exists for companies that focus on innovation.

There are more than a dozen major neurology franchises, and many companies have had blockbuster success in this market. Yet the unmet need and resulting opportunity in this market are staggering. What business strategies can companies utilize to tap this wide-open market? Most medicines on the market offer only symptomatic relief, and few new innovative drugs are in development. What approaches can companies use to create drugs with disease-modifying effects and to treat early-stage disease?

Companies are using many life-cycle management strategies to extend the market for existing drugs. While these drugs are useful, they do little to build value for the future. Why are so few products available for neurological diseases? What explains the lack of innovation in this market? What strategies are companies using to develop future neurology drug markets and franchises?

Scope of the report:

Overview of drugs and market for the four major neurology diseases: Alzheimer's disease, Parkinson's disease, epilepsy, and multiple sclerosis.

Key neurology deals: overview of ten neurology deals valued at more than $100 million that have closed within the last two years.

Business strategies that companies are using to develop future neurology drug markets and franchises: in-licensing, mergers and acquisitions, fully integrated companies, challenging drug patents, extending reach from generics to brands.

Decision points critical to innovation in the neurology market: resource allocation and prioritization, how to treat early-stage disease, creating personalized medicine, stem cell research.

Spectrum Expert Commentary: the view from a world-known pharmaceutical industry consultant.

Outlook: challenges that the neurology market will face without innovation.

Companies mentioned:

Abbott Laboratories

Acorda

Albany Molecular Research

Advanced

Neurolomodulation

Systems

Alnylam

Amarin

Astellas

AstraZeneca

Athenagen

Axaron Bioscience

Axonyx

Bayer AG

Carlsson Research

Celera Genomics

CeNeS

Chugai

Cita NeuroPharmaceuticals

CoCensys

Dainippon

DNAVEC

Durect

Eisai

Elan

Esteve

Forest Labs

Fumapharm

GeneMedix

Genzyme

GlaxoSmithKline

Ilex Oncology

Image-Guided Neurologics

Ivax

Janssen

Johnson & Johnson

Kyowa Hakko Kogyo

LION bioscience

Lundbeck

Medtronic

Merck KGaA

Millennium

Pharmaceuticals

MultiCell Technologies

Mutual Pharmaceutical

Mylan

Myriad Genetics

Neurochem

Neurocrine

NeuroSearch

NeuroSolutions

Newron Pharmaceuticals

Nitto Denko

Novartis

Novasite

NovImmune

Orion

Ortho-McNeil

Osprey Pharmaceutical

Ovation

PDL BioPharma

Pfi zer

Prolong Pharma

PsyCheNomics

Purdue Pharma

ReNeuron

Rinat Neuroscience

Roche

Sanofi -Aventis

Schering AG

Schwarz Pharma

Serono

Shire

Sigma-Tau

Solvay

St. Jude Medical

Stem Cell Sciences

Stem Cell Therapeutics

StemCells

Targacept

Teva

TorreyPines Therapeutics

Transition Therapeutics

TransTech Pharma

UCB

United Research

Laboratories

Valeant

Vernalis

Voyager

Watson Laboratories

XenoPort

Zapaq

Zenyaku Kogyo

For more information visit http://www.researchandmarkets.com/reports/c46402.

Source: Business Wire

More News in this Category